Journal article
50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA)
Abstract
Abstract Background PVZ remains the only licensed intervention to prevent severe RSV infection. The last formal cost-utility analysis (CUA) of its use in Canadian premature infants was published in 2010 (Smart J Med Econ 2010). Since then, the 3-variable International Risk Scoring tool (IRST) has been published (Blanken Pediatr Pulmonol 2018), which can guide prophylaxis for infants born 32-35 wGA at greatest risk of RSV hospitalization …
Authors
Fullarton J; Carbonell-Estrany X; Keary I; Rodgers-Gray B; Tarride J-E; Paes B
Journal
Paediatrics & Child Health, Vol. 28, No. Supplement_1, pp. e22–e22
Publisher
Oxford University Press (OUP)
Publication Date
September 23, 2023
DOI
10.1093/pch/pxad055.050
ISSN
1205-7088